Ravi Paluri to Treatment Outcome
This is a "connection" page, showing publications Ravi Paluri has written about Treatment Outcome.
Connection Strength
0.415
-
Alkashash AM, Elsebaie MA, Bikhet MH, Morsi M, Paluri RK. Predictors of Survival among Early Onset Pancreatic Adenocarcinoma Patients A Tertiary Care Center Experience. Chirurgia (Bucur). 2021 Jan-Feb; 116(1):24-33.
Score: 0.107
-
Paluri RK, Li P, Anderson A, Nandagopal L, McArdle T, Young M, Robert F, Naik G, Saleh M. First-In-Human Phase 1 Clinical Trials - A Single-Center Experience In The Era Of Modern Oncotherapeutics. Sci Rep. 2020 05 13; 10(1):7935.
Score: 0.102
-
Paluri R, Madan A, Li P, Jones B, Saleh M, Jerome M, Miley D, Keef J, Robert F. Phase 1b trial of nintedanib in combination with bevacizumab in patients with advanced solid tumors. Cancer Chemother Pharmacol. 2019 03; 83(3):551-559.
Score: 0.093
-
Kim H, Morgan DE, Schexnailder P, Navari RM, Williams GR, Bart Rose J, Li Y, Paluri R. Accurate Therapeutic Response Assessment of Pancreatic Ductal Adenocarcinoma Using Quantitative Dynamic Contrast-Enhanced Magnetic Resonance Imaging With a Point-of-Care Perfusion Phantom: A Pilot Study. Invest Radiol. 2019 01; 54(1):16-22.
Score: 0.093
-
Locke JA, Pond GR, Sonpavde G, Necchi A, Giannatempo P, Paluri RK, Niegisch G, Albers P, Buonerba C, Di Lorenzo G, Vaishampayan UN, North SA, Agarwal N, Hussain SA, Pal S, Eigl BJ. Cisplatin- Versus Non-Cisplatin-based First-Line Chemotherapy for Advanced Urothelial Carcinoma Previously Treated With Perioperative Cisplatin. Clin Genitourin Cancer. 2016 08; 14(4):331-40.
Score: 0.019